Tuesday, November 14, 2017 3:33:27 PM
Heat Biologics Inc. - Get News & Ratings Daily
Enter your email address below to get the latest news and analysts' ratings for Heat Biologics Inc. with our FREE daily email newsletter:
Recent Stories
Babcock International Group plc’s (BAB) “Buy” Rating Reaffirmed at Peel Hunt
Heat Biologics, Inc. (HTBX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Coca-Cola Company (The) (KO) Upgraded to “Outperform” by Wells Fargo & Company
Delek US Holdings, Inc. (DK) Upgraded by Wells Fargo & Company to “Outperform”
TheStreet, Inc. (TST) Issues Earnings Results
Booker Group PLC (BOK) Given “Buy” Rating at Peel Hunt
Games Workshop Group PLC’s (GAW) “Buy” Rating Reaffirmed at Peel Hunt
Genedrive PLC (GDR) Earns Buy Rating from Peel Hunt
James Cropper PLC (CRPR) Releases Earnings Results
Phillips 66 (PSX) Downgraded to Underweight at Barclays PLC
Hollysys Automation Technologies, Ltd. (HOLI) Posts Earnings Results, Beats Expectations By $0.04 EPS
FirstGroup plc (FGP) Releases Earnings Results, Beats Estimates By $0.40 EPS
Tyson Foods, Inc. (TSN) Announces Earnings Results, Beats Expectations By $0.05 EPS
Navient Co. (NAVI) Now Covered by Analysts at Barclays PLC
Barclays PLC Upgrades PBF Energy Inc. (PBF) to “Overweight”
Peel Hunt Reaffirms “Add” Rating for Chemring Group plc (CHG)
Marcus & Millichap, Inc. (MMI) Stock Rating Upgraded by Citigroup Inc.
Phoenix New Media Limited (FENG) Announces Earnings Results, Beats Estimates By $0.09 EPS
DHT Holdings, Inc. (DHT) Announces Earnings Results, Beats Estimates By $0.04 EPS
Carclo plc (CAR) Posts Earnings Results, Beats Estimates By $0.20 EPS
Heat Biologics, Inc. (HTBX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
November 14th, 2017 • 0 comments • Filed Under • by ABMN Staff
in
Share
Heat Biologics, Inc. (NASDAQ:HTBX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03, Bloomberg Earnings reports. Heat Biologics had a negative net margin of 1,479.67% and a negative return on equity of 148.01%.
Heat Biologics (NASDAQ HTBX) opened at $0.59 on Tuesday. Heat Biologics has a 1 year low of $0.46 and a 1 year high of $3.35.
Get Heat Biologics Inc. alerts:
Separately, Griffin Securities began coverage on shares of Heat Biologics in a research report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Heat Biologics has a consensus rating of “Hold” and an average price target of $2.13.
An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. lifted its stake in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 661,388 shares of the biopharmaceutical company’s stock after purchasing an additional 70,290 shares during the quarter. Vanguard Group Inc. owned about 1.86% of Heat Biologics worth $403,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.64% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Recent NHWK News
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:59:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:07 PM
- NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:57:14 PM
- NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University • GlobeNewswire Inc. • 12/21/2023 01:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:47:34 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM